These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32750422)

  • 1. Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation.
    Arcuri LJ; Schirmer M; Colares M; Maradei S; Tavares R; Moreira MCR; Araujo RC; Lerner D; Pacheco AGF
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):e275-e279. PubMed ID: 32750422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
    Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
    Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation.
    Kerbauy MN; Ribeiro AAF; Arcuri LJ; Kerbauy LN; da Silva CC; Camargo LFA; Machado CM; Hamerschlak N
    Transpl Infect Dis; 2021 Aug; 23(4):e13626. PubMed ID: 33900012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
    Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
    Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors.
    Busca A; Passera R; Pini M; Zallio F; Dellacasa C; Audisio E; Giaccone L; Maffini E; Costa C; Cavallo R; Bruno B
    Am J Hematol; 2015 Jun; 90(6):E117-21. PubMed ID: 25752810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation.
    Jeurkar C; Leiby B; Banks J; Leader A; Rudolph S; Mateja G; Rashid SA; Carabasi M; Filicko-O'Hara J; O'Hara W; Wagner JL; Gergis U; Flomenberg N; Grosso D
    Transplant Cell Ther; 2021 Apr; 27(4):327.e1-327.e11. PubMed ID: 33836876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia.
    Arcuri LJ; Nabhan SK; Cunha R; Nichele S; Ribeiro AAF; Fernandes JF; Daudt LE; Rodrigues ALM; Arrais-Rodrigues C; Seber A; Atta EH; de Oliveira JSR; Funke VAM; Loth G; Junior LGD; Paz A; Calixto RF; Gomes AA; Araujo CES; Colturato V; Simoes BP; Hamerschlak N; Flowers ME; Pasquini R; Rocha V; Bonfim C
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2311-2317. PubMed ID: 32949751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
    Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
    Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
    Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia.
    Lin CH; Su YJ; Hsu CY; Wang PN; Teng CJ
    Transpl Infect Dis; 2019 Aug; 21(4):e13096. PubMed ID: 31004545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
    Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
    Kanate AS; Mussetti A; Kharfan-Dabaja MA; Ahn KW; DiGilio A; Beitinjaneh A; Chhabra S; Fenske TS; Freytes C; Gale RP; Ganguly S; Hertzberg M; Klyuchnikov E; Lazarus HM; Olsson R; Perales MA; Rezvani A; Riches M; Saad A; Slavin S; Smith SM; Sureda A; Yared J; Ciurea S; Armand P; Salit R; Bolaños-Meade J; Hamadani M
    Blood; 2016 Feb; 127(7):938-47. PubMed ID: 26670632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
    Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
    Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation.
    Gao F; Shi Z; Shi J; Luo Y; Yu J; Fu H; Lai X; Liu L; Yuan Z; Zheng Z; Huang H; Zhao Y
    HLA; 2024 Jan; 103(1):e15320. PubMed ID: 38081622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
    Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
    Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Analysis of Cytomegalovirus Infection after Different Patterns of Hematopoietic Stem Cell Transplantation].
    Wang S; Liu DB; Zheng XL; Ding L; Han DM; Wang ZD; Yan HM; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1438-44. PubMed ID: 26524053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.